Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology ...

New York, USA-based rare neurological disease drug developer Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open ...

Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...

Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical ...

Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

San Francisco-based Trace Neuroscience has launched with $101 million in series A funding to develop ALS therapies focused on ...